ambrisentan

Known as: 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid, ambrisentan [Chemical/Ingredient], (+)-(2S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
This prospective, double-blinded, randomized controlled study aimed to investigate the efficacy and safety of oral tadalafil in… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2011
2011
BACKGROUND Ambrisentan is a selective endothelin-receptor antagonist that is approved by the US Food and Drug Administration for… (More)
Is this relevant?
2011
2011
Eisenmenger syndrome (ES) is a known complication of congenital heart disease associated with unrepaired systemic to pulmonary… (More)
Is this relevant?
2011
2011
BACKGROUND Sarcoidosis associated pulmonary hypertension (SAPH) is associated with significant morbidity and mortality. There is… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVES This study evaluated the safety and efficacy of ambrisentan for a period of 2 years in patients with pulmonary… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
The pharmacokinetic interaction between sildenafil, a phosphodiesterase type 5 (PDE-5) inhibitor, and ambrisentan, an ET(A… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
OBJECTIVES The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type… (More)
  • figure 1
Is this relevant?
Review
2002
Review
2002
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly… (More)
Is this relevant?